10-Bromo-5H-dibenzo[b,f]azepine-5-carboxamide
CAS: 59690-97-0
Rif. 3D-JCA69097
1g | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione |
Informazioni sul prodotto
- 5H-Dibenz[b,f]azepine-5-carboxamide, 10-bromo-
BZEA is a drug substance that has been detected in the urine of patients taking carbamazepine, a drug used to treat epilepsy. The debromination reaction of BZEA involves the conversion of bromine atoms to hydrogen atoms and the conversion of dibenzofurans to furans. The tetraethylammonium ion is an important reagent for this reaction. Iminodibenzyl (IDB) is a byproduct from this reaction. The polarographic method can be used to detect BZEA in solution or gas chromatography-mass spectrometry can be used to identify it. Chromatographic methods are useful for determining impurities, such as IDB, which may have been formed during the debromination process. Analytical methods are needed for determining sources of BZEA and its metabolite iminostilbene. Methanol is a common solvent used in analytical work on BZEA because it is less expensive than other